Targeting Macrophages in Atherosclerosis

Curr Pharm Biotechnol. 2021;22(15):2008-2018. doi: 10.2174/1389201022666210122142233.

Abstract

Atherosclerosis (AS) is an important pathological basis for the occurrence of Coronary Atherosclerotic Disease (CAD), stroke and other adverse cardiovascular events. AS is an inflammatory disease, and macrophages are the main inflammatory cells in AS lesions, playing a leading role in the formation of atherosclerotic plaques and the development and regression of AS. Various proinflammatory and anti-inflammatory factors act on macrophages to regulate AS. Pro-inflammatory factors recruit monocytes to accumulate in the inflammatory site and promote the transformation of monocytes to macrophages. A large number of aggregated macrophages secrete various inflammatory mediators to promote AS. Pro-inflammatory factors can induce the polarization of M1-type macrophages to start and maintain inflammation, promote the accumulation of lipids in macrophages, and accelerate the formation of foam cells. Anti-inflammatory factors can not only induce M2-type macrophages polarization, promote tissue remodeling and repair, and reduce the occurrence of AS, but also promote the metabolism of fatty acid oxidation and oxidative phosphorylation of macrophages, regulate lipid metabolism, stabilize plaques, and induce the transformation of helper T cells of type 1/2 (Th1/Th2) to Th2 cells, thus reducing inflammation. This review summarizes the effect and underlying regulatory mechanism of macrophages in the development of AS, which can provide new ideas for the diagnosis and treatment of AS targeting macrophages.

Keywords: Atherosclerosis; immunoreaction; inflammation; macrophages; pathogenesis; regulatory mechanism..

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Atherosclerosis* / drug therapy
  • Humans
  • Inflammation
  • Inflammation Mediators
  • Macrophages

Substances

  • Anti-Inflammatory Agents
  • Inflammation Mediators